DOCSLIB.ORG

Inhibition of Midkine Alleviates Experimental Autoimmune Encephalomyelitis Through the Expansion of Regulatory T Cell Population

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inhibition of Midkine Alleviates Experimental Autoimmune Encephalomyelitis Through the Expansion of Regulatory T Cell Population Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population Jinyan Wang*, Hideyuki Takeuchi*†, Yoshifumi Sonobe*, Shijie Jin*, Tetsuya Mizuno*, Shin Miyakawa‡, Masatoshi Fujiwara‡, Yoshikazu Nakamura§¶, Takuma Katoʈ, Hisako Muramatsu**, Takashi Muramatsu**††, and Akio Suzumura*† *Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan; ‡RIBOMIC, Inc., 3-15-5-601 Shirokanedai, Minato-ku, Tokyo 108-0071, Japan; §Department of Basic Medical Sciences, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan; ¶Core Research Evolutional Science and Technology, Japan Science and Technology Agency, Toyonaka, Osaka 560-8531, Japan; ʈDepartment of Bioregulation, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan; **Department of Biochemistry, Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan; and ††Department of Health Science, Faculty of Psychological and Physical Sciences, Aichi Gakuin University, Nisshin, Aichi 470-0195, Japan Edited by Ethan Shevach, National Institutes of Health, Bethesda, MD, and accepted by the Editorial Board January 20, 2008 (received for review October 12, 2007) CD4؉CD25؉ regulatory T (Treg) cells are crucial mediators of nity, and abnormalities in Treg cell function may contribute to the autoimmune tolerance. The factors that regulate Treg cells, how- development of autoimmune diseases (15–17). Thus, expansion of ever, are largely unknown. Here, we show that deficiency in the Treg cell population could prevent autoimmune attacks, in- midkine (MK), a heparin-binding growth factor involved in onco- cluding EAE (12–14, 18, 19). genesis, inflammation, and tissue repair, attenuated experimental Here, we show that MK deficiency attenuates myelin oligoden- autoimmune encephalomyelitis (EAE) because of an expansion of drocyte glycoprotein (MOG)-induced EAE due to an expansion of the Treg cell population in peripheral lymph nodes and decreased the Treg cell population in the peripheral lymph nodes, followed by numbers of autoreactive T-helper type 1 (T 1) and T 17 cells. MK H H decreases in the numbers of autoreactive TH1 and TH17 cells. decreased the Treg cell population ex vivo in a dose-dependent Moreover, administration of anti-MK RNA aptamers that effec- manner by suppression of STAT5 phosphorylation that is essential tively neutralize MK induced expansion of the Treg cell population for Foxp3 expression. Moreover, administration of anti-MK RNA and reduced the symptoms of EAE. This demonstrates that MK is aptamers significantly expanded the Treg cell population and a critical suppressor of Treg cell expansion. Moreover, inhibition of alleviated EAE symptoms. These observations indicate that MK MK using RNA aptamers may be a potent therapeutic strategy serves as a critical suppressor of Treg cell expansion, and inhibition against autoimmune diseases, including MS. of MK using RNA aptamers may provide an effective therapeutic strategy against autoimmune diseases, including multiple sclerosis. Results MK Deficiency Attenuates MOG-Induced EAE. To examine the immu- aptamer ͉ multiple sclerosis nological roles of MK, we generated MOG35–55-induced EAE in C57BL/6J WT and MK-deficient (MdkϪ/Ϫ) mice. Most of the WT idkine (MK), a heparin-binding growth factor, exerts pleio- mice exhibited clinical signs of the disease Ϸ12 days after the initial Mtropic effects, including cell proliferation, cell migration, immunization and developed peak EAE Ϸ18 days after immuni- angiogenesis, and fibrinolysis, in a variety of tissues (1). MK also zation as described previously (20, 21). Almost all of the MdkϪ/Ϫ plays important roles in the induction of oncogenesis, inflamma- mice also developed EAE. However, the clinical scores of the Ϫ Ϫ tion, and tissue repair. The overexpression of MK has been ob- Mdk / mice were significantly lower than those of the WT mice MEDICAL SCIENCES served in a number of malignant tumors (1). However, MK- (Fig. 1a). deficient mice are reportedly resistant to ischemic renal injury (2) To confirm whether the suppression of EAE in the MdkϪ/Ϫ mice and neointima formation in atherosclerosis (3). A recent study was due to MK deficiency, we administrated MK to the MdkϪ/Ϫ proposed that MK deficiency suppresses the development of a mice with s.c.-implanted microosmotic pumps for Ϸ16 days after rheumatoid arthritis model by preventing inflammatory leukocyte MOG immunization as described previously (3, 4). As shown in Fig. migration and osteoclast differentiation (4). Furthermore, MK Ϫ Ϫ 1, MK administration to Mdk / mice abolished the suppression of expression is up-regulated in the spinal cord during the induction EAE (MdkϪ/Ϫ ϩ MK) (Fig. 1a). However, the cessation of MK and progression phases of experimental autoimmune encephalo- administration resulted in regaining the attenuation of EAE in myelitis (EAE) (5). However, the precise immunological functions Ϫ/Ϫ ϩ of MK have yet to be elucidated. Mdk MK mice (starting 22 days after MOG immunization). Multiple sclerosis (MS) and its animal model, EAE, are auto- Histological analysis of the lumbar spinal cord revealed that immune diseases characterized by inflammatory demyelination in the CNS (6). Although MS and EAE have been described as Author contributions: J.W., H.T., and Y.S. contributed equally to this work; H.T. and A.S. T-helper type 1 (TH1) cell-mediated autoimmune diseases, TH17 designed research; J.W., H.T., Y.S., S.J., T.M., and T.K. performed research; S.M., M.F., Y.N., ϩ cells, a newly discovered lineage of CD4 T cells that secrete IL-17, H.M., and T.M. contributed new reagents/analytic tools; J.W., H.T., and Y.S. analyzed data; have recently been found to be critical for the development of and H.T. and A.S. wrote the paper. autoimmune diseases, including EAE (7–10). Various types of The authors declare no conflict of interest. immune cells and soluble mediators contribute to the complex This article is a PNAS Direct Submission. E.S. is a guest editor invited by the Editorial Board. mechanism underlying the onset and progression of MS, which is Freely available online through the PNAS open access option. characterized by autoreactive T cell infiltration and the activation †To whom correspondence may be addressed. E-mail: [email protected] or of microglia, the resident antigen-presenting cells in the CNS. In [email protected]. ϩ ϩ particular, CD4 CD25 regulatory T (Treg) cells have received a This article contains supporting information online at www.pnas.org/cgi/content/full/ great deal of attention as negative regulators of MS pathogenesis 0709592105/DC1. (11–14). Treg cells regulate peripheral tolerance and autoimmu- © 2008 by The National Academy of Sciences of the USA www.pnas.org͞cgi͞doi͞10.1073͞pnas.0709592105 PNAS ͉ March 11, 2008 ͉ vol. 105 ͉ no. 10 ͉ 3915–3920 Downloaded by guest on September 27, 2021 MdkϪ/Ϫ-EAE mice had fewer infiltrating inflammatory cells than WT-EAE mice (WT mice) (Fig. 1 b and e)(MdkϪ/Ϫ mice) (Fig. 1 c and f). MK administration also reversed this reduced level of CNS inflammation in the MdkϪ/Ϫ mice (MdkϪ/Ϫ ϩ MK mice) (Fig. 1 d and g). These histological findings agreed with the clinical data. Taken together, these data indicate that MK plays an important role in the induction and development of EAE and that these immunological effects of MK are transient and reversible. MK Deficiency Induces the Expansion of the CD4؉CD25؉Foxp3؉ Treg Cell Population in Peripheral Lymph Nodes. We then assessed the immunological differences between WT and MdkϪ/Ϫ mice after MOG immunization. First, we compared the expression profiles of antigen-presenting molecules [MHC class II, B7–1, B7–2, intercel- lular adhesion molecule (ICAM)-1, and vascular cell adhesion molecule (VCAM)-1], cytokines (TNF-␣, IL-1␤, IL-6, TGF-␤, and IL-12), chemokines [IFN-␥-inducible 10-kDa protein (IP-10) reg- ulated upon activation normal T cells expressed and secreted (RANTES), macrophage inflammatory protein-1␣ (MIP-1␣), and monocyte chemoattractant protein-1 (MCP-1)], and iNOS in mi- croglia or macrophages (as the antigen-presenting cells in the CNS or periphery, respectively). Before stimulation with LPS and IFN-␥, Ϫ/Ϫ ␤ Fig. 1. Attenuation of MOG-induced EAE in MK-deficient mice. (a) EAE Mdk microglia had higher B7–2, MCP-1, and IL-1 expression clinical scores for WT (filled squares; n ϭ 16), MdkϪ/Ϫ (open circles; n ϭ 13), and levels and lower ICAM-1 and MIP-1␣ expression levels than WT Ϫ Ϫ MK-administered MdkϪ/Ϫ mice (MdkϪ/Ϫ ϩ MK) (filled circles; n ϭ 13). MdkϪ/Ϫ microglia. In contrast, Mdk / macrophages had higher B7–1 and mice exhibited significantly lower clinical scores than WT mice (*, P Ͻ 0.01 vs. B7–2 expression levels than WT macrophages. After stimulation WT). MK administration to MdkϪ/Ϫ mice abrogated the attenuation of EAE. with LPS and IFN-␥, however, these differences were no longer After MK administration ceased (starting 22 days after MOG immunization), observed, except for decreased expression of VCAM-1 and MIP-1␣ Ϫ/Ϫ ϩ Mdk MK mice showed the partial suppression of EAE symptoms again (†, in MdkϪ/Ϫ microglia [supporting information (SI) Fig. 6a]. The total P Ͻ 0.05 vs. WT). (b–g) H&E staining of lumbar spinal cords from peak EAE mice. e, f, and g are higher-magnification images of the boxed areas in b, c, and d, number of mononuclear cells from the peripheral lymph nodes was Ϫ/Ϫ respectively. (Original magnification: b–d, ϫ100; e–g, ϫ400.) (b and e)WT similar between WT and Mdk mice (data not shown). Thus, we mice (score, 5) showed inflammatory cell infiltration in the spinal cord. (c and assessed subpopulations of T cells in the peripheral lymph nodes.
Load more

Recommended publications
  • Immunomodulation and Generation of Tolerogenic Dendritic Cells by Probiotic Bacteria in Patients with Inflammatory Bowel Disease
    International Journal of Molecular Sciences Article Immunomodulation and Generation of Tolerogenic Dendritic Cells by Probiotic Bacteria in Patients with Inflammatory Bowel Disease 1, 2, 1 Shaghayegh Baradaran Ghavami y, Abbas Yadegar y , Hamid Asadzadeh Aghdaei , Dario Sorrentino 3,4,*, Maryam Farmani 1 , Adil Shamim Mir 5, Masoumeh Azimirad 2 , Hedieh Balaii 6, Shabnam Shahrokh 6 and Mohammad Reza Zali 6 1 Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran; [email protected] (S.B.G.); [email protected] (H.A.A.); [email protected] (M.F.) 2 Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran; [email protected] (A.Y.); [email protected] (M.A.) 3 IBD Center, Division of Gastroenterology, Virginia Tech Carilion School of Medicine, Roanoke, VA 24016, USA 4 Department of Clinical and Experimental Medical Sciences, University of Udine School of Medicine, 33100 Udine, Italy 5 Department of Internal Medicine, Roanoke Memorial Hospital, Carilion Clinic, VA 24014, USA; [email protected] 6 Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran; [email protected] (H.B.); [email protected] (S.S.); [email protected] (M.R.Z.) * Correspondence: [email protected] These authors equally contributed to this study. y Received: 7 August 2020; Accepted: 27 August 2020; Published: 29 August 2020 Abstract: In inflammatory bowel diseases (IBD), the therapeutic benefit and mucosal healing from specific probiotics may relate to the modulation of dendritic cells (DCs).
    [Show full text]
  • Galectin-4 Interaction with CD14 Triggers the Differentiation of Monocytes Into Macrophage-Like Cells Via the MAPK Signaling Pathway
    Immune Netw. 2019 Jun;19(3):e17 https://doi.org/10.4110/in.2019.19.e17 pISSN 1598-2629·eISSN 2092-6685 Original Article Galectin-4 Interaction with CD14 Triggers the Differentiation of Monocytes into Macrophage-like Cells via the MAPK Signaling Pathway So-Hee Hong 1,2,3,4,5, Jun-Seop Shin 1,2,3,5, Hyunwoo Chung 1,2,4,5, Chung-Gyu Park 1,2,3,4,5,* 1Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul 03080, Korea 2Institute of Endemic Diseases, Seoul National University College of Medicine, Seoul 03080, Korea 3Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea 4Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea 5Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul 03080, Korea Received: Jan 28, 2019 ABSTRACT Revised: May 13, 2019 Accepted: May 19, 2019 Galectin-4 (Gal-4) is a β-galactoside-binding protein mostly expressed in the gastrointestinal *Correspondence to tract of animals. Although intensive functional studies have been done for other galectin Chung-Gyu Park isoforms, the immunoregulatory function of Gal-4 still remains ambiguous. Here, we Department of Microbiology and Immunology, Seoul National University College of Medicine, demonstrated that Gal-4 could bind to CD14 on monocytes and induce their differentiation 103 Daehak-ro, Jongno-gu, Seoul 03080, into macrophage-like cells through the MAPK signaling pathway. Gal-4 induced the phenotypic Korea. changes on monocytes by altering the expression of various surface molecules, and induced E-mail: [email protected] functional changes such as increased cytokine production and matrix metalloproteinase expression and reduced phagocytic capacity.
    [Show full text]
  • B Cell Checkpoints in Autoimmune Rheumatic Diseases
    REVIEWS B cell checkpoints in autoimmune rheumatic diseases Samuel J. S. Rubin1,2,3, Michelle S. Bloom1,2,3 and William H. Robinson1,2,3* Abstract | B cells have important functions in the pathogenesis of autoimmune diseases, including autoimmune rheumatic diseases. In addition to producing autoantibodies, B cells contribute to autoimmunity by serving as professional antigen- presenting cells (APCs), producing cytokines, and through additional mechanisms. B cell activation and effector functions are regulated by immune checkpoints, including both activating and inhibitory checkpoint receptors that contribute to the regulation of B cell tolerance, activation, antigen presentation, T cell help, class switching, antibody production and cytokine production. The various activating checkpoint receptors include B cell activating receptors that engage with cognate receptors on T cells or other cells, as well as Toll-like receptors that can provide dual stimulation to B cells via co- engagement with the B cell receptor. Furthermore, various inhibitory checkpoint receptors, including B cell inhibitory receptors, have important functions in regulating B cell development, activation and effector functions. Therapeutically targeting B cell checkpoints represents a promising strategy for the treatment of a variety of autoimmune rheumatic diseases. Antibody- dependent B cells are multifunctional lymphocytes that contribute that serve as precursors to and thereby give rise to acti- cell- mediated cytotoxicity to the pathogenesis of autoimmune diseases
    [Show full text]
  • The Immunological Synapse and CD28-CD80 Interactions Shannon K
    © 2001 Nature Publishing Group http://immunol.nature.com ARTICLES The immunological synapse and CD28-CD80 interactions Shannon K. Bromley1,Andrea Iaboni2, Simon J. Davis2,Adrian Whitty3, Jonathan M. Green4, Andrey S. Shaw1,ArthurWeiss5 and Michael L. Dustin5,6 Published online: 19 November 2001, DOI: 10.1038/ni737 According to the two-signal model of T cell activation, costimulatory molecules augment T cell receptor (TCR) signaling, whereas adhesion molecules enhance TCR–MHC-peptide recognition.The structure and binding properties of CD28 imply that it may perform both functions, blurring the distinction between adhesion and costimulatory molecules. Our results show that CD28 on naïve T cells does not support adhesion and has little or no capacity for directly enhancing TCR–MHC- peptide interactions. Instead of being dependent on costimulatory signaling, we propose that a key function of the immunological synapse is to generate a cellular microenvironment that favors the interactions of potent secondary signaling molecules, such as CD28. The T cell receptor (TCR) interaction with complexes of peptide and as CD2 and CD48, which suggests that CD28 might have a dual role as major histocompatibility complex (pMHC) is central to the T cell an adhesion and a signaling molecule4. Coengagement of CD28 with response. However, efficient T cell activation also requires the partici- the TCR has a number of effects on T cell activation; these include pation of additional cell-surface receptors that engage nonpolymorphic increasing sensitivity to TCR stimulation and increasing the survival of ligands on antigen-presenting cells (APCs). Some of these molecules T cells after stimulation5. CD80-transfected APCs have been used to are involved in the “physical embrace” between T cells and APCs and assess the temporal relationship of TCR and CD28 signaling, as initiat- are characterized as adhesion molecules.
    [Show full text]
  • Induces Antigen Presentation in B Cells Cell-Activating Factor of The
    B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells This information is current as of September 27, 2021. Min Yang, Hidenori Hase, Diana Legarda-Addison, Leena Varughese, Brian Seed and Adrian T. Ting J Immunol 2005; 175:2814-2824; ; doi: 10.4049/jimmunol.175.5.2814 http://www.jimmunol.org/content/175/5/2814 Downloaded from References This article cites 54 articles, 36 of which you can access for free at: http://www.jimmunol.org/content/175/5/2814.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells1 Min Yang,* Hidenori Hase,* Diana Legarda-Addison,* Leena Varughese,* Brian Seed,† and Adrian T.
    [Show full text]
  • Induce EBV-Transformed B Cell Apoptosis Through the Fas/Fasl Pathway
    INTERNATIONAL JOURNAL OF ONCOLOGY 43: 1531-1540, 2013 CD80 (B7.1) and CD86 (B7.2) induce EBV-transformed B cell apoptosis through the Fas/FasL pathway GA BIN PARK1, YEONG SEOK KIM1, HYUN-KYUNG LEE2, DAE-HO CHO3, DAEJIN KIM1 and DAE YOUNG HUR1 1Department of Anatomy and Research Center for Tumor Immunology, Inje University College of Medicine; 2Department of Internal Medicine, Inje University Busan Paik Hospital, Busan 614-735; 3Department of Life Science, Sookmyung Women's University, Yongsan-gu, Yongsan-ku, Seoul 140-742, Republic of Korea Received July 7, 2013; Accepted August 16, 2013 DOI: 10.3892/ijo.2013.2091 Abstract. CD80 and CD86 expression is strongly regulated resting human B lymphocytes with EBV results in immor- in B cells and is induced by various stimuli (e.g., cytokines, talization of infected B cells, yielding lymphoblastoid cells, ligation of MHC class II and CD40 ligand). Epstein-Barr virus which are characterized by continuous growth and resistance (EBV) infection activates B lymphocytes and transforms them to various apoptotic signals. Moreover, lymphoblastoid cells into lymphoblastoid cells. However, the role of CD80 and CD86 have a phenotype related to that of activated B-lymphoblasts. in EBV infection of B cells remains unclear. Here, we observed However, despite clarification of the role of some viral proteins, that cross-linking of CD80 and CD86 in EBV-transformed such as latent membrane protein (LMP), in EBV-related resis- B cells induced apoptosis through caspase-dependent release tance, the molecular mechanisms of resistance to apoptosis are of apoptosis-related molecules, cytochrome c and apoptosis- not yet fully understood (2,3).
    [Show full text]
  • Loss of the Death Receptor CD95 (Fas) Expression by Dendritic Cells Protects from a Chronic Viral Infection
    Loss of the death receptor CD95 (Fas) expression by dendritic cells protects from a chronic viral infection Vineeth Varanasia, Aly Azeem Khanb, and Alexander V. Chervonskya,1 aDepartment of Pathology and Committee on Immunology, and bInstitute for Genomics and Systems Biology and Department of Human Genetics, The University of Chicago, Chicago, IL 60637 Edited* by Alexander Y. Rudensky, Memorial Sloan–Kettering Cancer Center, New York, NY, and approved May 5, 2014 (received for review January 28, 2014) Chronic viral infections incapacitate adaptive immune responses persistsinparenchymatousorganssuchaskidneys(13,15).In by “exhausting” virus-specific T cells, inducing their deletion and contrast, infection with the Armstrong variant of LCMV is rapidly reducing productive T-cell memory. Viral infection rapidly induces cleared, does not cause exhaustion of T cells, and results in the death receptor CD95 (Fas) expression by dendritic cells (DCs), mak- formation of a good memory T-cell response. Animals carrying ing them susceptible to elimination by the immune response. Lym- loxP-flanked Fas exon IX (B6.FasKI) and CD11c-driven Cre phocytic choriomeningitis virus (LCMV) clone 13, which normally recombinase (B6.CD11c-Cre) were infected with LCMV clone 13. establishes a chronic infection, is rapidly cleared in C57Black6/J Cre-negative FasKI mice as well as mice with a T-cell–specific mice with conditional deletion of Fas in DCs. The immune response deletion of Fas (B6.Lck-Cre.FasKI) served as controls (Fig. 1). to LCMV is characterized by an extended survival of virus-specific Viral titers were determined in the secondary lymphoid organs effector T cells. Moreover, transfer of Fas-negative DCs from non- and kidneys.
    [Show full text]
  • Anti-Human CD80/B7.1
    Product Information Sheet Anti-Human CD80 (B7-1)-162Dy Catalog #: 3162010B Clone: 2D10.4 Package Size: 100 tests Isotype: Mouse IgG1 Storage: Store product at 4°C. Do not freeze. Formulation: Antibody stabilizer with 0.05% Sodium Azide Cross Reactivity: Rhesus Technical Information Validation: Each lot of conjugated antibody is quality control tested by CyTOF® analysis of stained cells using the appropriate positive and negative cell staining and/or activation controls. Recommended Usage: The suggested use is 1 µl for up to 3 X 106 live cells in 100 µl. It is recommended that the antibody be titrated for optimal performance for each of the desired applications. Human Daudi cells (top) and human Jurkat T cells (bottom) stained with 162Dy- anti-CD80 [B7.1] (2D10.4). Description CD80 (B7.1) is a 60 kDa member of the B7 family of proteins. CD80 is expressed by activated B and T lymphocytes, macrophages and dendritic cells. While CD80 can bind to the immune-stimulatory CD28, it binds with higher affinity to the immune-inhibitory CTLA-4. The B7 ligands CD80 and CD86 and their receptors CD28 and CTLA-4 act create a costimulatory-coinhibitory system that acts to regulate immune responses. Mice deficient in CD80 and CD86 have profound defects in both humoral and cellular immunity. References Bandura, D. R., et al. Mass Cytometry: Technique for Real Time Single Cell Multitarget Immunoassay Based on Inductively Coupled Plasma Time-of-Flight Mass Spectrometry. Analytical Chemistry 81:6813-6822, 2009. Ornatsky, O. I., et al. Highly multiparametric analysis by mass cytometry. J Immunol Methods 361 (1-2):1-20, 2010.
    [Show full text]
  • The Functional in Vitro Response to CD40 Ligation Reflects a Different
    Leukemia (2011) 25, 1760–1767 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu ORIGINAL ARTICLE The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia This article has been corrected since advance Online Publication, and a corrigendum is also printed in this issue C Scielzo1,2,9, B Apollonio1,3,4,9, L Scarfo` 5,6, A Janus6, M Muzio1,4, E ten Hacken3,6, P Ghia3,6,7,8 and F Caligaris-Cappio1,3,7,8 1Laboratory of Lymphoid Malignancies, Division of Molecular Oncology, Istituto Scientifico San Raffaele, Milan, Italy; 2Unversita` degli studi di Milano, Milan, Italy; 3Universita` Vita-Salute San Raffaele, Milan, Italy; 4Laboratory of cell activation and signalling, Division of Molecular Oncology, Istituto Scientifico San Raffaele, Milan, Italy; 5Haematology Section, University of Ferrara, Ferrara, Italy; 6Laboratory of B Cell Neoplasia, Division of Molecular Oncology, Istituto Scientifico San Raffaele, Milan, Italy; 7Unit of Lymphoid Malignancies, Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy and 8MAGIC (Microenvironment and Genes in Cancers of the blood) Interdivisional Research Program, Istituto Scientifico San Raffaele, Milan, Italy Malignant B lymphocytes from chronic lymphocytic leukemia who have a poorer clinical outcome and tend to express other (CLL) patients maintain the capacity to respond to CD40 negative prognostic factors (for example, ZAP70 or CD38 ligation, among other microenvironmental stimuli.
    [Show full text]
  • CD4 T Cells Transduced with CD80 and 4-1BBL Mrna Induce Long
    J Immunother Cancer: first published as 10.1186/2051-1426-2-S3-P264 on 6 November 2014. Downloaded from Cho et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P264 http://www.immunotherapyofcancer.org/content/2/S3/P264 POSTERPRESENTATION Open Access CD4 T cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T cell responses resulting in potent antitumor effects Hyun-Il Cho1*, Hye-Mi Park2, Hyun-Jung Shon1, Tai-Gyu Kim2 From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA. 6-9 November 2014 Therapeutic cancer vaccines are an attractive alternative to Microbiology, Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Korea, Republic Of. conventional therapies to treat malignant tumors, and more importantly, to prevent recurrence after primary Published: 6 November 2014 therapy. However, the availability of professional antigen- presenting cells (APCs) has been restricted by difficulties encountered in obtaining sufficient professional APCs for doi:10.1186/2051-1426-2-S3-P264 clinical use. We have prepared an alternative cellular vac- Cite this article as: Cho et al.: CD4 T cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T cell responses resulting in cine with CD4 T cells that can be expanded easily to yield potent antitumor effects. Journal for ImmunoTherapy of Cancer 2014 2 a pure and homogeneous population in vitro. To enhance (Suppl 3):P264. their potency as a therapeutic vaccine, in vitro expanded CD4 T cells were transfected with RNAs encoding the costimulatory ligands CD80, 4-1BBL, or both (CD80-T, 4-1BBL-T, and CD80/4-1BBL-T cells, respectively).
    [Show full text]
  • Transient Blocking of Both B7.1 (CD80) and B7.2 (CD86) in Addition
    Gene Therapy (2002) 9, 537–546 2002 Nature Publishing Group All rights reserved 0969-7128/02 $25.00 www.nature.com/gt RESEARCH ARTICLE Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40–CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector C Ziller1, F Stoeckel1, L Boon2 and H Haegel-Kronenberger1 1TRANSGENE, Strasbourg, France; and 2Tanox Pharma BV, Amsterdam, The Netherlands Blockade of the CD40–CD40L and CD80/CD86–CD28 of the immune response against Ad. Using either of these costimulatory pathways represents a strategy to inhibit the mAb pairs, a second vector could be administered 1 month immune response against Ad vectors designed for gene after the first injection but with lower efficiency than in naive therapy applications. Since most previous studies have used animals. Thus, CD86 stands as the pivotal B7 molecule a CTLA4-Ig fusion molecule binding to both CD80 and involved in the development of the immune response against CD86, the respective roles of these B7 molecules remained Ad. However, only the blockade of both CD80 and CD86 undefined. We have studied the effect of blocking mono- in addition to CD40L fully inhibited the humoral and cellular clonal Abs (mAbs) directed against the costimulatory mol- responses against the Ad vector, such that readministration ecules CD40L, CD80 and CD86, alone or in different combi- after 1 month was as efficient as in naive animals. At the nations, on the humoral and cellular immune responses time of readministration, treated animals had regained their against Ad. Groups of mice were transiently treated with ability to mount a normal immune response to the second each combination of blocking mAbs upon systemic injection Ad vector, showing that tolerance was not induced.
    [Show full text]
  • Early Enhancement in Antigen Presentation and CD80 on the Cell
    CD40-Induced Aggregation of MHC Class II and CD80 on the Cell Surface Leads to an Early Enhancement in Antigen Presentation This information is current as Abigail Clatza, Laura C. Bonifaz, Dario A. A. Vignali and of September 26, 2021. José Moreno J Immunol 2003; 171:6478-6487; ; doi: 10.4049/jimmunol.171.12.6478 http://www.jimmunol.org/content/171/12/6478 Downloaded from References This article cites 65 articles, 32 of which you can access for free at: http://www.jimmunol.org/content/171/12/6478.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology CD40-Induced Aggregation of MHC Class II and CD80 on the Cell Surface Leads to an Early Enhancement in Antigen Presentation1 Abigail Clatza,* Laura C. Bonifaz,* Dario A. A. Vignali,† and Jose´Moreno2* Ligation of CD40 on B cells increases their ability to present Ag and to activate MHC class II (MHC-II)-restricted T cells.
    [Show full text]